Skip to search formSkip to main contentSkip to account menu

NEOD001

Known as: Anti-amyloid Monoclonal Antibody NEOD001 
A monoclonal antibody against amyloid with potential use in the treatment of amyloid light chain (AL) and AA amyloidosis. Upon intravenous… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Antibodies, Monoclonal, Humanized
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement.
Review
2018
Review
2018
Novel Approaches for the Management of AL Amyloidosis
Purpose of ReviewLight-chain-associated (AL) amyloidosis is a rare disease with a poor prognosis. However, we have made recent… 
2018
2018
Faculty Opinions recommendation of First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
  • P. Hari
  • Faculty Opinions – Post-Publication Peer Review…
  • 2018
  • Corpus ID: 81138468
2016
2016
Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid‐directed monoclonal antibody
To the Editor: Amyloid light chain (AL) amyloidosis is a rare disease caused by the tissue deposition of misfolded immunoglobulin… 
2016
2016
NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study
Introduction: Systemic amyloidoses are a group of rare disorders characterized by the accumulation of misfolded proteins in… 
2016
2016
Organ Biomarker Responses in Patients With Light Chain Amyloidosis Treated With NEOD001 Are Independent of Previous Hematologic Response
2016
2016
Neod001 Demonstrates Cardiac and Renal Biomarker Responses in a Phase 1/2 Study in Patients With Amyloid Light Chain Amyloidosis and Persistent Organ Dysfunction
2016
2016
NEOD001 Demonstrates Cardiac Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction in a Phase 1/2 Study Expansion
2015
2015
The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction.
TPS8614 Background: Light chain (AL) amyloidosis is a rare disease caused by the deposition of misfolded proteins that cause… 
2015
2015
NEOD001 Demonstrates Cardiac and Renal Biomarker Responses in a Phase 1/2 Study in Patients With AL Amyloidosis and Persistent Organ Dysfunction
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)